ERBB2 and breast carcinoma: Finally, ARX788 is a highly homogeneous novel ADC consisting of a HER2-targeting antibody and a potent anti-tubulin payload (AS269), that demonstrated efficacy in the phase II ACE-Breast-03 trial in T-DM1 pre-treated advanced breast cancer (ABC).